Triplet Therapy Shows Promise in Gastric Cancer
A phase 2 trial combining regorafenib, chemotherapy and nivolumab met its primary endpoint in advanced gastric cancer patients.
Updated on Nov. 5, 2026 in Cancer
In a phase 2 trial, a combination of regorafenib, chemotherapy and the immunotherapy nivolumab was given to 30 patients with advanced gastric cancer. The treatment was safe, and 22 of the 30 patients showed an objective tumor response, meeting the study's primary endpoint.
Why it matters
Median survival for gastric cancer remains low, at roughly 13 to 15 months on average, which is driving researchers to test combination strategies. The trial's immune-cell findings suggest the regimen may reshape the tumor environment to strengthen the body's own attack on cancer.
The phase 2 trial enrolled 30 patients, and 22 of them displayed an objective tumor response, while the study's sample size is small and its longer-term outcomes were not reported in the source. Researchers still need to clarify how regorafenib interacts with the other agents and how it influences anti-tumor immunity.
The players
Science Translational Medicine
A peer-reviewed journal published by the American Association for the Advancement of Science that carries translational research studies.
The details
Researchers combined regorafenib, chemotherapy and the anti-PD-1 immunotherapy nivolumab in the phase 2 study. Single-cell RNA sequencing of biopsies showed the regimen boosted anti-tumor CD8+ T cells while suppressing regulatory T cells and cancer-associated fibroblasts.
Timeline
Results of the phase 2 trial were published on November 5, 2026.
Health Landscape
The study extends the research line testing anti-PD-1 immunotherapies such as nivolumab in combination with other agents for gastric cancer, a disease whose median survival has stayed in the 13 to 15 month range. It reflects a broader push among oncologists to move beyond single-agent treatment for advanced tumors.
For patients with advanced gastric cancer, combination regimens like this one could in future offer another treatment path if larger studies confirm the response rates. Patients and families should discuss any new option with their oncology team, since the regimen is still in early-phase testing.
The takeaway
Combination immunotherapy strategies are gaining ground as researchers look for ways to lift survival in gastric cancer beyond the current 13 to 15 month median. Larger trials will determine whether the early tumor-response signal holds up.
Further reading
Explore more on Cancer to see how combination immunotherapies are being tested across tumor types.
More information
Read the original peer-reviewed study in Science Translational Medicine for the full trial methods and results.
Source note: This article includes information reported by News-Medical.
